Mitochondrial biogenesis factor PGC-1α suppresses spinal morphine tolerance by reducing mitochondrial superoxide

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Opioid use disorders (OUDs) are a major public health crisis in the United States.
• Chronic opioid use for pain management is limited by the development of antinociceptive/analgesic tolerance.
• Mitochondrial dysfunction and increased reactive oxygen species (ROS) are implicated in morphine tolerance (MT).

Purpose of the Study:

• To investigate the role of Peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1α) and ROS in morphine tolerance (MT).
• To determine if PGC-1α can mitigate MT and associated mitochondrial oxidative stress.

Main Methods:

• Morphine tolerance was induced in Sprague-Dawley rats via intrathecal morphine administration.
• Behavioral tests (von Frey, hot plate) assessed antinociception.
• Spinal cord dorsal horn (SCDH) PGC-1α expression, mitochondrial superoxide levels, and effects of rPGC-1α and Mito-Tempol were analyzed.

Main Results:

• Spinal MT decreased PGC-1α expression in SCDH neurons.
• Recombinant PGC-1α (rPGC-1α) administration reversed MT and reduced mitochondrial superoxide.
• Mito-Tempol, a superoxide scavenger, also reduced MT behavioral responses.

Conclusions:

• Spinal PGC-1α plays a crucial role in modulating morphine tolerance.
• Restoring PGC-1α levels may represent a novel therapeutic strategy to combat opioid tolerance by reducing mitochondrial oxidative stress in the SCDH.